docetaxel anhydrous has been researched along with resveratrol in 10 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (resveratrol) | Trials (resveratrol) | Recent Studies (post-2010) (resveratrol) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 10,931 | 241 | 7,998 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Djeu, JY; Gilvary, DL; Sallman, DA; Wei, S; Zhong, B; Zhou, J | 1 |
| Al-Abd, AM; El-Eraky, WI; El-Latif, HA; El-Moselhy, MA; El-Shemy, HA; El-Sherbiny, GA; Mahmoud, AM; Nofal, SM | 1 |
| Acosta, EP; Banerjee, S; Lillard, JW; Singh, R; Singh, SK | 1 |
| Xie, Y; Yao, Y | 1 |
| Lillard, JW; Singh, R; Singh, SK | 1 |
| Dai, G; Han, Q; Shi, Y; Song, Z | 1 |
| Christensen, M; Doughty, H; Kenealey, J; Lawson, J; Oblad, R | 1 |
| Chen, Y; Gao, D; Han, Y; Lin, Y; Lin, Z; Wang, F; Wang, P; Wang, Y; Yuan, H; Zhang, L | 1 |
| Behroozaghdam, M; Bishayee, A; De Greef, D; Dehghani, M; Hasani Sadi, F; Hashemi, M; Javanshir, S; Kamali, D; Mirzaei, S; Rashidi, M; Tabari, T; Zabolian, A; Zarepour, A; Zarrabi, A | 1 |
| Baheti, A; Bhargava, P; Chaugule, D; Gota, V; Jadhav, S; Jadhav, VK; Mandavkar, S; Mittra, I; Ostwal, V; Peelay, Z; Ramaswamy, A; Shinde, S; Srinivas, S; Tandel, H | 1 |
1 review(s) available for docetaxel anhydrous and resveratrol
| Article | Year |
|---|---|
Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cisplatin; Docetaxel; Doxorubicin; Female; Humans; Paclitaxel; Polyphenols; Resveratrol; Stilbenes; Tumor Microenvironment; Water | 2022 |
1 trial(s) available for docetaxel anhydrous and resveratrol
| Article | Year |
|---|---|
A pro-oxidant combination of resveratrol and copper reduces chemotherapy-related non-haematological toxicities in advanced gastric cancer: results of a prospective open label phase II single-arm study (RESCU III study).
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Copper; Docetaxel; Female; Humans; Male; Middle Aged; Prospective Studies; Reactive Oxygen Species; Resveratrol; Stomach Neoplasms | 2022 |
8 other study(ies) available for docetaxel anhydrous and resveratrol
| Article | Year |
|---|---|
Clusterin mediates TRAIL resistance in prostate tumor cells.
Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Clusterin; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Neoplastic; Humans; Janus Kinases; Male; Prostatic Neoplasms; Proto-Oncogene Proteins pp60(c-src); Receptors, TNF-Related Apoptosis-Inducing Ligand; Resveratrol; RNA, Small Interfering; STAT Transcription Factors; Stilbenes; Taxoids; TNF-Related Apoptosis-Inducing Ligand | 2007 |
Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-2-Associated X Protein; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Humans; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Resveratrol; Stilbenes; Structure-Activity Relationship; Taxoids; Tumor Cells, Cultured | 2011 |
Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53/ p21WAF1/CIP1 and p27KIP1 pathway.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Docetaxel; Drug Synergism; Humans; Immunoblotting; Male; Microscopy, Fluorescence; Prostatic Neoplasms; Resveratrol; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Stilbenes; Taxoids; Tumor Suppressor Protein p53 | 2017 |
Octenylsuccinate hydroxypropyl phytoglycogen, a dendrimer-like biopolymer, solubilizes poorly water-soluble active pharmaceutical ingredients.
Topics: Celecoxib; Dendrimers; Docetaxel; Fenofibrate; Glycogen; Griseofulvin; Pharmaceutic Aids; Resveratrol; Solubility; Solvents; Stilbenes; Succinates; Surface-Active Agents; Taxoids | 2018 |
Reversal of drug resistance by planetary ball milled (PBM) nanoparticle loaded with resveratrol and docetaxel in prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Folic Acid; Humans; Male; Nanoparticles; Prostatic Neoplasms; Resveratrol | 2018 |
Endothelial growth factor receptor-targeted and reactive oxygen species-responsive lung cancer therapy by docetaxel and resveratrol encapsulated lipid-polymer hybrid nanoparticles.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Carriers; Drug Compounding; Drug Liberation; Drug Synergism; Endothelial Growth Factors; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Particle Size; Polyethylene Glycols; Reactive Oxygen Species; Receptors, Vascular Endothelial Growth Factor; Resveratrol; Stearic Acids; Stilbenes; Surface Properties; Taxoids | 2018 |
Application of Mixture Design Response Surface Methodology for Combination Chemotherapy in PC-3 Human Prostate Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dioxolanes; Docetaxel; Drug Synergism; Flavonoids; Humans; Male; Mitoxantrone; Models, Statistical; Piperidines; Prostatic Neoplasms; Resveratrol; Taxoids | 2018 |
Co-delivery of Docetaxel and Resveratrol by liposomes synergistically boosts antitumor efficiency against prostate cancer.
Topics: Animals; Antineoplastic Agents; Caspase 3; Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Humans; Liposomes; Male; Mice; Mice, Nude; Prostatic Neoplasms; Resveratrol | 2022 |